<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

Adavosertib

Cancer    Adavosertib

Adavosertib speeds cancer cells into the wall of mitotic catastrophe

A cancer cell is like a racecar, speeding through the process of cellular replication. But it has to stop at the G2M cell cycle checkpoint, where a race inspector called Wee1 checks it over for damage – cells with intact DNA can continue, while cells with damaged DNA have to stick around for repairs. The wait is worth it – there are curves ahead, and beyond the G2M checkpoint, cells with damaged DNA explode against the wall of “mitotic catastrophe.” But the thing is, we want cancer cells to explode; we would rather they speed through the G2M checkpoint without a Wee1 inspection and hit the wall of mitotic catastrophe.


Author Cancer Center | Publish Date April 01, 2019
Full Story

CU Cancer Center In the News

MHealthIntelligence

Leveraging RPM to Enable At-Home Care for High-Risk Cancer Patients

news outletMHealthIntelligence
Publish DateFebruary 05, 2024

Glen Peterson, DNP, ACNP, RN, from CU Cancer Center, discusses RPM & telehealth benefits for cancer patients on Healthcare Strategies podcast.

Full Story
9News

Sunday is World Cancer Day

news outlet9News
Publish DateFebruary 04, 2024

CU Anschutz oncologist and CU Cancer Center member Dr. Wells Messersmith shares insights: Colorado braces for over 29,000 cancer cases in the coming year.

Full Story
Cure Today

An Oncologist Explains How She Uses ctDNA in Gastric Cancer

news outletCure Today
Publish DateJanuary 24, 2024

CU Cancer Center member Sunnie Kim, MD, discussed how she uses ctDNA in treating patients with gastric or esophageal cancer.

Full Story
DocWire News

Toxicities and Duration of Treatment for Immunotherapy in Advanced Metastatic Hepatocellular Carcinoma

news outletDocWire News
Publish DateJanuary 23, 2024

CU Cancer Center member Christopher Lieu, MD, and Namrata Vijayvergia, MD, of the Fox Chase Cancer Center conclude their discussion with considerations for managing immunotherapy-related toxicities in patients with metastatic hepatocellular carcinoma (HCC), along with a review of the available evidence regarding the duration of immunotherapy treatment.

Full Story